Showing 1851-1860 of 2034 results for "".
- Regenxbio Reports Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-reports-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2476800/As part of its quarterly results reporting, Regenxbio provided an update on its phase 1/2a for RGX-314 for the treatment of wet AMD. “We are encouraged by the continued positive interim data from the phase 1/2a RGX-314 trial and the potential of NAV gene therapy as a one-time treatm
- Bascom Palmer Eye Institute Ranked Nation’s No. 1 in Ophthalmologyhttps://modernod.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology/2476783/U.S News & World Report has once again ranked Bascom Palmer Eye Institute of the University of Miami Health System as the nation’s best in ophthalmology. Recognized as a global leader in vision research, medical education, and patient care, this year marks the 18th time that Bascom P
- PolyActiva Completes Recruitment in Phase 1 Glaucoma Implant Safety Studyhttps://modernod.com/news/polyactiva-completes-recruitment-in-phase-1-glaucoma-implant-safety-study/2476759/PolyActiva has completed patient enrollment for its phase 1 clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma. Current glaucoma treatment requires eye drops to be administered daily, often multiple times each day
- Visual Cortical Prosthesis Is Tested at Baylor College of Medicinehttps://modernod.com/news/visual-cortical-prosthesis-is-tested-at-baylor-college-of-medicine/2476698/In a dark room inside Baylor College of Medicine, study participants are asked to look at a blacked out computer screen and point to a white square that appears at intervals on different locations on the monitor. The majority of the time they can successfully point to the square, even though each
- Ocutech Adds 3x and 5.5x Power Options for the Falcon Autofocus Bioptichttps://modernod.com/news/ocutech-adds-3x-and-5-5x-power-options-for-the-falcon-autofocus-bioptic/2476672/The Ocutech Falcon Autofocus Bioptic self-focusing low vision telescope is now available in 3x, 4x and 5.5x powers. Released in late 2018 in its original 4x power, the Falcon Autofocus bioptic is now being prescribed in the US and in 11 foreign countries. The Falcon’s Time-of-Flight (ToF)
- Brits in the Dark Over Eye Health According to Orbis UKhttps://modernod.com/news/brits-in-the-dark-over-eye-health-according-to-orbis-uk/2476651/New research reveals that over half of Brits (53%) do not get their eyes tested every 2 years as recommended, and just over 1 in 10 (11%) can’t remember the last time they went to the optician. This is despite 45% of those surveyed listing sight as their most valuable sense. The surv
- Medical Specialty Organizations Applaud Introduction of Congressional Legislation to Improve Transparency in Prior Authorizationhttps://modernod.com/news/medical-specialty-organizations-applaud-introduction-of-congressional-legislation-to-improve-oversight-and-transparency-in-prior-authorization/2476633/A coalition of eight national medical specialties, including the American Academy of Ophthalmology, pledged support for the bipartisan “Improving Seniors’ Timely Access to Care Act of 2019” (H.R. 3107) legislation that aims to protect patients from unreasonable Medicare Advantag
- Ocular Therapeutix OTX-TP Intracanalicular Insert Fails to Meet Phase 3 Endpointhttps://modernod.com/news/ocular-therapeutix-otx-tp-intracanalicular-insert-fails-to-meet-phase-3-endpoint/2476598/Ocular Therapeutix’s intracanalicular insert failed to meet its primary endpoint of statistically significant superiority in mean reduction of IOP compared with placebo at all nine time points, according to a company news release. OTX-TP is an intracanalicular insert that delivers a
- Tilak Healthcare Announces Exclusive Partnership for Co-Promotion with Novartis Francehttps://modernod.com/news/tilak-healthcare-announces-exclusive-partnership-for-co-promotion-with-novartis-france/2476578/Tilak Healthcare, a video game studio specializing in mobile medical games for patients with chronic diseases, announced an exclusive co-promotion partnership with Novartis France for OdySight, its first clinically validated mobile game to monitor vision remotely. Tilak He
- New Mobile Platform Records Patient Outcomes After Cataract Surgeryhttps://modernod.com/news/new-mobile-platform-records-patient-outcomes-after-cataract-surgery/2476543/Rayner has developed RayPRO, a mobile phone and web-based app for collecting patient-reported outcomes (PROs) for 3 years after surgery. The company says this is the first time such software has been available for free to ophthalmic surgeons. It is a bespoke platform that has been specific